Cagrilintide: difference between revisions
Diff·revision 11 → 12·12:00, 11 Jan 2025
Difference between revision 11 and revision 12 of Cagrilintide. 8 lines changed; the page grew by 177 bytes.
| Revision 11 — 23:44, 29 Dec 2024 ExenatideEzra (talk) add the discontinued indication with its date 2,970 bytes ±0 | Revision 12 — 12:00, 11 Jan 2025 ConsensusConal (talk) add the excipient list from the labelling 3,147 bytes +177 | ||
|---|---|---|---|
| 26 | Gastrointestinal adverse events dominate, as with the incretin agonists, and are concentrated during escalation. Whether combining two agents that both delay gastric emptying compounds them is addressed only indirectly by the published designs.{{r|hay2015}} | 26 | Gastrointestinal adverse events dominate, as with the incretin agonists, and are concentrated during escalation. Whether combining two agents that both delay gastric emptying compounds them is addressed only indirectly by the published designs.{{r|hay2015}} |
| 27 | 27 | ||
| + | 28 | No cardiovascular or other outcome evidence exists for this compound.{{r|lau2021}} | |
| + | 29 | ||
| 28 | == References == | 30 | == References == |
| 29 | {{reflist}} | 31 | {{reflist}} |
| 30 | <ref name="lau2021">Lau DCW, Erichsen L, Francisco AM, et al. "Once-weekly cagrilintide for weight management in people with overweight and obesity." ''The Lancet'' 398(10317):2160–2172 (2021). PMID 34798060.</ref> | 32 | <ref name="lau2021">Lau DCW, Erichsen L, Francisco AM, et al. "Once-weekly cagrilintide for weight management in people with overweight and obesity." ''The Lancet'' 398(10317):2160–2172 (2021). PMID 34798060.</ref> |
| 31 | <ref name="hay2015">Hay DL, Chen S, Lutz TA, Parkes DG, Roth JD. "Amylin: pharmacology, physiology, and clinical potential." ''Pharmacological Reviews'' 67(3):564–600 (2015). PMID 26071095.</ref> | 33 | <ref name="hay2015">Hay DL, Chen S, Lutz TA, Parkes DG, Roth JD. "Amylin: pharmacology, physiology, and clinical potential." ''Pharmacological Reviews'' 67(3):564–600 (2015). PMID 26071095.</ref> |
| + | 34 | ||
| + | 35 | == See also == | |
| + | 36 | * [[Amylin]] | |
| + | 37 | * [[Amylin receptor agonist]] | |
| + | 38 | * [[CagriSema]] | |
| + | 39 | * [[Semaglutide]] | |
| 32 | 40 | ||
| 33 | {{DEFAULTSORT:Cagrilintide}} | 41 | {{DEFAULTSORT:Cagrilintide}} |